Merck KGaA has entered a collaboration with China-based biotech BeiGene to research a new treatment for cancer.

New Drug Approvals

Merck KGaA HQ Darmstadt

Merck KGaA has entered a collaboration with China-based biotech BeiGene to research a new treatment for cancer.

The compound, currently known as BeiGene-283, BGB-283 , is a second-generation BRAF inhibitor and is expected to enter clinical development in 2014.

It is designed to work by hindering the action of the BRAF protein, which is thought to play a part in the promotion of cancer cell growth and has been found to be mutated in some cancer patients.

read all at

http://www.pmlive.com/pharma_news/merck_kgaa_to_research_cancer_drug_with_chinese_biotech_480521

 

View original post

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s